Marea Therapeutics Announces Breakthrough Phase II Results for MAR001, a Novel Monoclonal Antibody Targeting Remnant Cholesterol
Positive Phase II Data:
Marea Therapeutics has announced positive topline results from the Phase IIa study of MAR001, a monoclonal antibody targeting ANGPTL4, which demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides134.
Target Mechanism:
MAR001 targets ANGPTL4, a protein highly expressed in adipose tissue, aiming to lower remnant cholesterol, which is a significant factor in cardiovascular disease risk even when LDL cholesterol is optimally controlled134.
Clinical Trial Details:
The Phase IIa study enrolled 55 participants with hypertriglyceridemia, showing approximately 50% placebo-corrected remnant cholesterol lowering in the target population at doses of 300mg and 450mg, predicting meaningful clinical benefit134.
Safety Profile:
MAR001 was generally well tolerated, with no serious adverse events or deaths reported in any arm of the study134.
Future Plans:
Marea expects to initiate a Phase IIb clinical trial with MAR001 in the first half of 2025, further advancing the development of this potential first-in-class treatment for residual cardiovascular risk134.
Additional Pipeline:
Marea also announced its second lead pipeline program, MAR002, an anti-growth hormone receptor antibody for the treatment of acromegaly, with a Phase I trial expected to initiate in the second half of 2025134.
Sources:
1. https://www.biospace.com/drug-development/marea-posts-positive-phase-ii-data-for-remnant-cholesterol-lowering-mab
3. https://www.biospace.com/press-releases/marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001-for-cardiovascular-disease-and-disclosure-of-second-lead-pipeline-program-for-the-treatment-of-acromegaly
4. https://www.mareatx.com/press-releases/marea-therapeutics-provides-update-on-corporate-progress-including-positive-topline-results-from-phase-2a-clinical-trial-of-mar001/